Clinical Trial Update: CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial completed evaluating the safety and efficacy of QTORIN 3.9% sirolimus topical gel for preventing basal cell carcinomas in patients with G…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma
• Nevoid Basal Cell Carcinoma Syndrome

Drugs mentioned

• QTORIN 3.9% Sirolimus Topical Gel (sirolimus topical gel)

Snippet

Sponsor: Palvella Therapeutics, Inc. | Conditions: BCCs in Gorlin Syndrome Patients | Phase 2 | Status: COMPLETED